Geyser Brands Inc. announced a robust and healthy second harvest. Geyser Brands has also tripled its growing capacity for an output of 51,000 grams of CBD-dominant flower, with the aim of researching optimal cannabinoid profiles for its conditions-based healthcare products. Geyser Brands' vision is to supply consumer healthcare products to both Canadian and global markets with its line of hemp-derived oil and proposed CBD healthcare offerings to the consumer and pet care sector. These products will include special formulations that assist in the improvement of a wide range of specific healthcare conditions. Already holding a cultivation license from Health Canada, Geyser Brands has also applied for processing and sales licenses to enable it to legally infuse its expected line of health and wellness products with cannabinoids. Geyser Brands intends to infuse its products with hemp-derived oils and CBD, and to sell them in Canada and abroad. Health Canada's proposed regulations for cannabis edibles, extracts, and topicals are expected to be adopted into law in October 2019. Geyser Brands intends to be a leader in this new industry. Further to Geyser Brands' commitment to the health and wellness community, it has also submitted an application to Health Canada to upgrade its facility to include mothering and cloning rooms. Geyser Brands has entered into talks with Health Canada approved seed banks and LPs to secure high-CBD seed strains to ensure consistent cannabinoid profiles for its brands and products. This will not only ensure greater control over its value chain, but will also solidify its cost efficiencies to allow further re-investment in future R&D.